Spojené štáty - angličtina - NLM (National Library of Medicine)

aventis pharma ltd. - oxaliplatin (unii: 04zr38536j) (oxaliplatin - unii:04zr38536j) - oxaliplatin 5 mg in 1 ml

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited - oxaliplatin - pdr for soln for infusion - 5 mg/ml

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited t/a sanofi - oxaliplatin - pdr for soln for infusion - 5 mg/ml

Malajzia - angličtina - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

sanofi-aventis (malaysia) sdn. bhd. - oxaliplatin -

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - oxaliplatin 100mg;   - powder for infusion - 100 mg - active: oxaliplatin 100mg   excipient: lactose monohydrate

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - oxaliplatin 50mg;   - powder for infusion - 50 mg - active: oxaliplatin 50mg   excipient: lactose monohydrate

Izrael - angličtina - Ministry of Health

sanofi - aventis israel ltd - oxaliplatin 5 mg/ml - concentrate for solution for infusion - oxaliplatin - in combination with 5- fluorouracil and folinic acid (fa), oxaliplatin is indicated for: - adjuvant treatment of stage iii ( duke's c) colon cancer after complete resection of primary tumour - the treatment of metastatic colorectal cancer.

Izrael - angličtina - Ministry of Health

sanofi - aventis israel ltd - oxaliplatin 5 mg/ml - concentrate for solution for infusion - oxaliplatin - in combination with 5- fluorouracil and folinic acid (fa), oxaliplatin is indicated for: - adjuvant treatment of stage iii ( duke's c) colon cancer after complete resection of primary tumour - the treatment of metastatic colorectal cancer.